Overview
Bright Minds Biosciences designs next-generation serotonergic compounds targeting specific 5-HT receptor subtypes to treat epilepsy, PTSD, and addiction with reduced side effects. Their platform leverages computational drug design to create highly selective psychedelic-inspired molecules.
More in Mental Health Tech
Latest industry news
Tether Evo Tackles Brain-Computer Interface's Most Stubborn Engineering Problem
2026-09-04 · Research
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
Company details
Category
💙 Mental Health Tech
Location
Vancouver, Canada
Funding
Public · NASDAQ: DRUG
Website
brightmindsbiosciences.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →